Efficacy and Safety of Microsomal Ferric Pyrophosphate Supplement for Iron Deficiency Anemia in Pregnancy

IntroductionAnemia during pregnancy is characterized by decreased hemoglobin levels. Iron deficiency poses asignificant global health concern, especially in pregnant women, where increased iron demands are crucialfor both maternal and fetal well-being. MethodIn the current study, we investigated the effectiveness and safety of 30 mg SunActiveTM Fe (Taiyo GmbH,Yokkaichi, Japan), emulsified microsomalTM ferric pyrophosphate (EMFP) tablets in treating iron deficiencyanemia in 27 second-trimester singleton pregnant women. ResultsOur study results demonstrated that hemoglobin levels increased significantly within 30 days of treatmentand continued to remain higher than baseline throughout the study. Serum ferritin levels exhibited a 6.61-fold increase, maintaining elevated levels consistently. Serum iron also increased significantly by 46.9%.Additionally, symptoms such as nausea, breathlessness, dizziness, irritability, and heartburn were notablyreduced, leading to improved quality of life. Subjects reported decreased overall fatigue, indicating anenhanced quality of life. Babies born during the study showed healthy birth weights, with uncomplicateddeliveries. High treatment compliance of 99.5% underscored patient commitment to the study. Furthermore,the investigational product demonstrated a favorable safety profile, with only two mild adverse eventsobserved, unrelated to the treatment. Conclusion These findings suggest that EMFP could be a valuable therapeutic option for managing iron deficiencyanemia in pregnant women, promoting better maternal and fetal outcomes. Further research with anincreased sample size is warranted to delve into the underlying mechanisms behind these positiveoutcomes, nonetheless, our study provides a promising foundation for addressing this critical health issue